Latest Conference Articles

Joseph Rossano, MD, MPH, discusses the 56-week active-treatment period of the SCOUT-HCM trial, which demonstrated the sustainability of mavacamten’s effects.

New survey data from 42 countries show high antiviral adherence among people with hepatitis B, but 64% of those untreated receive no hepatitis B care.

Pharmacovigilance data on 328 pregnancies exposed to glecaprevir/pibrentasvir presented at AASLD 2026 showed no vertical transmission and no pattern of congenital anomalies.

Christie Ballantyne, MD, discusses his analysis of the CORALreef Lipids trial, highlighting enlicitide’s effects on LDL-C, ApoB, Lp(a), and non-HDL-C.

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

ALTUS data show the multi-target HCC blood test score tracks tumor size, Milan status, and LI-RADS category rather than liver disease severity.

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

Luke Laffin, MD, discusses the open-label extension from Launch-HTN, which further investigated the efficacy of lorundrostat in uncontrolled hypertension.

Michelle O’Donoghue, MD, discusses the results of Part A of the TYDAL-TIMI 78 trial, demonstrating MAR001’s comparative efficacy to placebo.

Liver stiffness, bilirubin, and symptoms can guide when to start second-line PBC therapy as ALP normalization becomes achievable for more patients.

Dave Singh, MD, discusses IL-33 inhibition for non-type 2 COPD, 2027 GOLD report refinements, and how to view biologics not yet in the GOLD algorithm.

MAESTRO-NASH data show early liver fat reductions on MRI-PDFF predict biopsy-confirmed MASH resolution and fibrosis improvement with resmetirom.

Phase 2 data show zabopegdutide, a dual GLP-1/glucagon agonist, improved fibrosis and drove MASH resolution vs placebo at 48 weeks.

The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.

Robert Rosenson, MD, discusses the long-term extension of the phase 3 PALISADE trial, which demonstrated plozasiran’s association with lower ApoC3 and fasting TG.

Most patients with type 2 COPD also have non-type 2 inflammation, shaping how clinicians may use targeted and anti-alarmin biologics, per Dave Singh, MD.

Pavel Strnad, MD, discusses interim RestorAATion-2 data showing RNA editing with WVE-006 restored functional M-AAT and reduced Z-AAT in Pi*ZZ AATD.

Jörn Schattenberg, MD, discusses phase 2b data showing efinopegdutide improved MASH resolution and fibrosis vs placebo, with an open-label semaglutide arm.

Sachdev explains how VasCog-2-WSO criteria integrate new MRI markers, biomarkers, and unified terminology for vascular dementia.

Meena Bansal, MD, discusses data showing resmetirom lowered Lp(a) and LDL regardless of statin use, plus real-world liver outcomes in nearly 4900 patients.

The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.

TRIUMPH-3 pharmacokinetic data show once-daily trientine tetrahydrochloride achieved exposure comparable to twice-daily dosing for Wilson disease.

Real-world REASON data suggest NCC-Sp, a measure of bioavailable copper, can track treatment response across therapies in unstable Wilson disease.

Jorg Taubel, MD, discusses data showing a single dose of CIDEB siRNA cut liver fat by up to 80% and normalized it in 62% of patients with MASLD.

Behnood Bikdeli, MD, MS, discusses his long-term follow-up to the HI-PRO study, which noted apixaban’s lasting effects on venous thromboembolism.

Topline results presented at The Liver Meeting showed 79% of patients with HDV reached undetectable HDV RNA at 48 weeks with monthly elebsiran plus tobevibart.

Ryan Tedford, MD, discusses his analysis of the phase 2 CADENCE trial, highlighting sotatercept’s beneficial effects on both the right and left sides of the heart.

Douglas Dieterich, MD, discusses AZURE-1 data showing brelovitug responses in chronic hepatitis D continued to improve with treatment beyond Week 24.